Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juni 2023

Genmab — Juni 2023

Planlagt Fastgjort Låst Flyttet Genmab
702 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #92

    Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma https://www.jnj.com/janssen-presents-longer-term-data-for-tecvayli-teclistamab-cqyv-showing-a-duration-of-response-of-22-months-in-patients-with-relapsed-or-refractory-multiple-myeloma

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #93

      J&J’s multiple myeloma combo produces déjà vu with 96% Carvykti-like response https://www.fiercebiotech.com/biotech/jjs-new-multiple-myeloma-combo-produces-deja-vu-96-carvykti-response

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #94

        Jamen er det ikke hvad vi altid har sagt? Og når de så lægger dara oveni, så får vi ORR-rater på 105%. 🙂 Jeg tør slet ikke tænke på, hvad der vi når op på, når superdara kommer.

        1 Reply Last reply
        0
        • B Offline
          B Offline
          bibob
          wrote on sidst redigeret af
          #95

          Fra ASCO. https://www.fiercebiotech.com/biotech/jjs-new-multiple-myeloma-combo-produces-deja-vu-96-carvykti-response?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech+Tracker&oly_enc_id=6900G6464778A3A

          1 Reply Last reply
          0
          • B Offline
            B Offline
            bibob
            wrote on sidst redigeret af
            #96

            Sorry. Havde ikke set E L link 21.07 😉

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #97

              https://www.bt.dk/udland/nyt-studie-overrasker-pille-halverer-risikoen-for-at-doe-af-lungekraeft Osimertinib vækker opsigt. Amivantamab går efter det marked (Tagrisso) i kombi med Lazertinib.

              1 Reply Last reply
              0
              • P Offline
                P Offline
                Pensionisten
                wrote on sidst redigeret af
                #98

                Fireside Goldman Sachs - desværre ikke Jan, der deltager (link)

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  Pensionisten
                  wrote on sidst redigeret af
                  #99

                  https://ir.genmab.com/genmab-news#content

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #100

                    Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (GMAB – Research Report) today and set a price target of $51.00.

                    1 Reply Last reply
                    0
                    • K Offline
                      K Offline
                      Klarussen
                      wrote on sidst redigeret af
                      #101

                      Lyder meget rimeligt

                      1 Reply Last reply
                      0
                      • B Offline
                        B Offline
                        bikube
                        wrote on sidst redigeret af
                        #102

                        Den 22. maj hævede han fra 47 til 51. Det svarer til lidt over 3500 i DK.

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #103

                          Lidt om Car-T https://endpts.com/new-car-t-data-look-spectacular-but-how-many-patients-will-take-it-and-when-asco23/

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #104

                            longer term results of patients with DLBCL treated with epcoritamab+R-CHOP. The latest results support the preliminary data and this treatment induces high CMR rates with a manageable safety profile https://twitter.com/lymphomahub/status/1666142892270682128

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #105

                              Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt

                              1 Reply Last reply
                              0
                              • BulderB Offline
                                BulderB Offline
                                Bulder
                                wrote on sidst redigeret af
                                #106

                                Link Preview Image
                                Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt

                                De amerikanske lægemiddelmyndigheder FDA har godkendt det bispecifikke antistof epcoritamab til behandling af patienter med relaps eller refraktært (r/r) storce

                                favicon

                                (haematologisktidsskrift.dk)

                                1 Reply Last reply
                                0
                                • BulderB Offline
                                  BulderB Offline
                                  Bulder
                                  wrote on sidst redigeret af
                                  #107

                                  God og grundig artikel, der belyser “styrkeforholdet” epco/glofi/car-t.

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    Pensionisten
                                    wrote on sidst redigeret af
                                    #108

                                    Tak for den gode artikel, @Bulder. Den var til at forstå - selv for mig! Og det siger ikke så lidt 😉

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #109

                                      Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma https://www.onclive.com/view/epcoritamab-plus-rituximab-lenalidomide-produces-responses-in-high-risk-r-r-follicular-lymphoma (this was the oral presentation)

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #110

                                        Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.7506?af=R

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #111

                                          so the first article is the new/later cutoff date of January 31, 2023; results very similar

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper